Tag: toxSYN
Amgen and Synafix Sign US $2 Billion License Agreement
Netherlands-based Synaffix, a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), confirmed that it had signed...
Kyowa Kirin Expands License Agreement with Synaffix
Japanese pharmaceutical and biotechnology company Kyowa Kirin has expanded its license agreement with The Netherlands based Synaffix with one new antibody-drug conjugates (ADC) target added to...
Dutch Biotech Signs License Agreement with Chinese ADC Developer
The Dutch biotech company Synaffix has signed a license agreement with the Chinese ADC developer Shanghai Miracogen. The agreement is estimated to be worth...
New ADC Payload Platform – Synaffix Launches toxSYN™
The Netherlands-based biotech company Synaffix, which has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates or ADCs, launched of a...
